U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula C14H14N2O6S3.2Na
Molecular Weight 448.445
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SULFOXONE SODIUM

SMILES

[Na+].[Na+].[O-]S(=O)CNC1=CC=C(C=C1)S(=O)(=O)C2=CC=C(NCS([O-])=O)C=C2

InChI

InChIKey=AZBNFLZFSZDPQF-UHFFFAOYSA-L
InChI=1S/C14H16N2O6S3.2Na/c17-23(18)9-15-11-1-5-13(6-2-11)25(21,22)14-7-3-12(4-8-14)16-10-24(19)20;;/h1-8,15-16H,9-10H2,(H,17,18)(H,19,20);;/q;2*+1/p-2

HIDE SMILES / InChI

Molecular Formula Na
Molecular Weight 22.98976928
Charge 1
Count
MOL RATIO 2 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C14H14N2O6S3
Molecular Weight 402.466
Charge -2
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Sulfoxone is a water-soluble sulfone and is a competitive inhibitor of the bacterial enzyme dihydropteroate synthetase. Sulfoxone under the brand name Diasone was used as an antileprosy drug, for treatment of dermatitis herpetiformis, and to treat pulmonary tuberculosis. Presently, usage of diasone has been discontinued.

Approval Year

Targets

Primary TargetPharmacologyConditionPotency

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
DIASONE SODIUM
Primary
DIASONE SODIUM
Primary
DIASONE SODIUM

Cmax

ValueDoseCo-administeredAnalytePopulation
600 ng/mL
330 mg single, oral
DAPSONE plasma
Homo sapiens

Doses

AEs

Sourcing

PubMed

Sample Use Guides

In Vivo Use Guide
Unknown
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Record UNII
57OWB0Q221
Record Status Validated (UNII)
Record Version